Opus Genetics Stock Surges 38.75% Amid Positive Trials
By ATTN Desk · Editorial oversight: Sean Han
OPUS GENETICS INC (NASDAQ: IRD)
Company Overview
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing gene therapies and ophthalmic treatments for inherited retinal diseases (IRDs) and other vision disorders. Following its all-stock acquisition by Ocuphire Pharma on October 22, 2024, the combined entity was renamed Opus Genetics, Inc., trading under the ticker IRD as of October 24, 2024.
Corporate Structure
- Headquarters: Research Triangle Park, North Carolina
- Industry: Biotechnology Research
- Employee Count: 11–50
- Leadership highlights:
- George Magrath, M.D., Chief Executive Officer
- Ben Yerxa, Ph.D., President
- Jean Bennett, M.D., Ph.D., Scientific Co-Founder and Board Member
- Adrienne Graves, Ph.D., Independent Director
Pipeline and Programs
| Program | Indication | Modality | Development Stage |
|---|---|---|---|
| OPGx-LCA5 | Leber congenital amaurosis (LCA5 mutations) | AAV-based gene therapy | Phase 1/2 (open-label) |
| OPGx-BEST1 | Best vitelliform macular dystrophy | AAV-based gene therapy | Initiation planned in 2025 |
| Phentolamine Ophthalmic Solution | Presbyopia; mesopic vision after LASIK | Topical α-antagonist (0.75%) | Phase 3 (LYNX-2; VEGA-3) |
| APX3330 | Non-proliferative diabetic retinopathy (DR) | Oral Ref-1 inhibitor | Pre-Phase 3 (FDA SPA agreed) |
Recent Developments
- October 22, 2024: Ocuphire Pharma announces all-stock acquisition of Opus Genetics, Inc.; combined company renamed Opus Genetics, Inc.
- December 2024: Six-month data from the OPGx-LCA5 trial show visual improvement in three patients with LCA5 mutations.
- May 4–8, 2025 (ARVO 2025): Presentation of 12-month OPGx-LCA5 data indicates improvements in cone-mediated vision and other functional areas.
- May 13, 2025 (ASGCT 2025): Poster on MERTK gene therapy in RCS rats highlights preclinical advances.
- May 15, 2025:
- Form 10-Q filed for the quarter ended March 31, 2025.
- Schedule 13G discloses Nantahala Capital Management’s 9.99% beneficial ownership.
- May 21, 2025: FDA grants Regenerative Medicine Advanced Therapy (RMAT) designation to OPGx-LCA5.
- March 21, 2025: Underwritten public offering raises $20 million; concurrent private placement adds $1.5 million (up to $43 million with full warrant exercise).
- June 2, 2025: Stock closes at $1.3799, reflecting a 38.75% increase on volume of 763,279 shares.
Financial and Strategic Analysis
| Metric | Value |
|---|---|
| Share Price (June 2, 2025) | $1.3799 (+38.75%) |
| Volume (June 2, 2025) | 763,279 shares |
| Market Capitalization | $59.3 million |
| Price/Sales (TTM) | 2.12 |
| Price/Book (MRQ) | 11.70 |
| Beta (5Y Monthly) | 0.29 |
| Revenue (TTM) | $13.65 million |
| Net Loss (TTM) | $58.62 million |
| Cash and Short-Term Investments | $41.79 million (MRQ) |
| Cash Runway | Into 2026 |
Strategic highlights:
- Capital Formation: $21.5 million raised in March 2025, with additional capital potential of $21.4 million from warrant exercises tied to OPGx-BEST1 data milestones.
- Regulatory Milestones:
- RMAT designation for OPGx-LCA5 accelerates the pathway to pivotal trials.
- FDA-agreed SPA for oral APX3330 Phase 3 trial in diabetic retinopathy.
- Pipeline Diversification: Combines late-stage ophthalmic small molecules (Phentolamine) with AAV-based gene therapies targeting multiple IRDs.
Market Position and Industry Context
- Opus Genetics specializes in rare inherited retinal diseases, an area with significant unmet medical need and limited approved therapies.
- Competitive landscape includes other gene therapy developers and ophthalmic drug companies pursuing small-molecule solutions.
- Engagement in major scientific conferences (ARVO, ASGCT, AOS) reinforces its position within the vision research community.
- Orphan Drug and Rare Pediatric Disease designations enhance commercial potential and access to priority review vouchers upon BLA approval.
tl;dr
- June 2, 2025: OPUS GENETICS stock increases 38.75% to $1.38 on substantial trading volume.
- March 21, 2025: $21.5 million financing completed, with potential total proceeds of up to $43 million tied to OPGx-BEST1 data release.
- May 2025: FDA grants RMAT to OPGx-LCA5; ARVO 2025 data indicate sustained visual improvements over 12 months.
- Phase 3 topline data for Phentolamine Ophthalmic Solution (LYNX-2, VEGA-3) expected mid-2025; APX3330 Phase 3 SPA established.
- Cash runway secured into 2026, supporting multiple clinical milestones.